Xeris Biopharma Holdings, Inc. XERS Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s total cost of revenue?
- Xeris Biopharma Holdings, Inc. (XERS) reported total cost of revenue of $10.57M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s total cost of revenue changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total cost of revenue increased by 21.2% year-over-year, from $8.73M to $10.57M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total cost of revenue?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total cost of revenue has grown at a 33.7% compound annual growth rate (CAGR), from $13.32M to $42.57M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.